2018 Clinical Development Pharmacokinetics 
The Pharma Data
DECEMBER 14, 2020
The trial, which will explore the pharmacokinetics and safety of ATX01 in healthy volunteers, is due to start in January 2021. AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. More information at www.algotx.com.
The Pharma Data
DECEMBER 21, 2020
UBX1325 is developed from BM-962, a Bcl-xL inhibiting compound licensed to UNITY by Ascentage Pharma for the treatment of age-related diseases. This progress in clinical development qualifies Ascentage Pharma for a milestone payment according to the terms of the licensing agreement. SUZHOU, China and ROCKVILLE, Md. ,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 13, 2020
Zai Labs obtained regional development and commercialization rights for the programs in mainland China, Hong Kong, Macau and Taiwan. Zai Lab is leading clinical development in its territory. “We That collaboration was to develop and commercialize four oncology antibody biosimilar therapies.
Drug Target Review
OCTOBER 3, 2024
These assays may include pharmacokinetic (PK) assays, which provide information on the drug’s properties, and immunogenicity assays for the detection of anti-drug antibodies (ADA), which can lead to adverse events and reduced efficacy. 2018 Dec 5;11(1):178–90. Journal of Molecular Biology. 2011 Oct 1;413(1):261–78.
The Pharma Data
NOVEMBER 8, 2020
The submission includes data from the ENLIGHTEN clinical development program in schizophrenia, and pharmacokinetic (PK) bridging data comparing ALKS 3831 and Zyprexa (olanzapine), to support an indication for schizophrenia. Celgene acquired it in 2018 from bluebird bio, who originally developed the therapy.
The Pharma Data
AUGUST 19, 2021
Vice President, Clinical Development, Solid Tumors, Janssen Research & Development, LLC. “We In 2018, Janssen Biotech, Inc. entered into a license and collaboration agreement with Yuhan Corporation for the development of lazertinib. **In 2018, Janssen Biotech, Inc. 8] , [9] , [10] , [11] , [12]. **In
Metabolite Tales Blog
APRIL 4, 2023
link] [2] Zhang and Tang, 2018. Drug metabolism in drug discovery and development. 2018 Sep;8(5):721-732. The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans. Br J Pharmacol. 2008 Mar;153 Suppl 1(Suppl 1):S82-9. Acta Pharm Sin B. link] [3] Bauman et al.,
Expert insights. Personalized for you.
52 
Let's personalize your content